STOCK TITAN

Inogen (INGN) Stock Price, News & Analysis

INGN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
22 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+13.5% close of October 1, 2026
1-year change
-19.6% closing prices, November 20, 2025 to November 20, 2026
1-month change
-20.8% closing prices, October 20, 2026 to November 20, 2026

Company Description

Inogen, Inc. (Nasdaq: INGN) is a medical technology company in the respiratory care space, aligned with the surgical and medical instrument manufacturing industry. The company focuses on respiratory products for use in the homecare setting, supporting patients who suffer from chronic respiratory conditions and require oxygen therapy or related treatments outside of the hospital environment.

According to its public disclosures, Inogen supports patient respiratory care by developing, manufacturing, and marketing respiratory therapy devices. These devices are used to deliver care to patients with chronic respiratory conditions and are made available through a network that includes patients, prescribers, home medical equipment providers, and distributors. This approach is intended to make respiratory therapy products widely available so that patients can better manage the impact of their disease.

Business focus and product portfolio

Inogen describes itself as a global medical technology company offering respiratory products for homecare use. Historically known for portable oxygen concentrators, the company’s portfolio has expanded to include additional respiratory therapy devices and accessories. Recent company communications highlight products such as the Voxi 5 stationary oxygen concentrator, which is designed to enhance access to oxygen therapy for long-term care patients in the United States, and Aurora CPAP masks, which are aimed at patients indicated for obstructive sleep apnea.

Inogen’s devices and accessories are positioned for use in home and long-term care environments. The company’s stationary and portable oxygen concentrators are used to deliver oxygen therapy to patients with chronic respiratory conditions, while its CPAP masks are designed for patients using continuous positive airway pressure devices for sleep apnea. These offerings support Inogen’s stated evolution toward a broader homecare respiratory solutions company.

Channels and customers

Inogen partners with home medical equipment providers and distributors, and also works directly with patients and prescribers. Its disclosures note that it sells products to home medical equipment providers and, in some cases, rents products directly to patients. Internationally, the company has indicated that it sells products through distributors, large gas companies, and home oxygen providers. This mix of business-to-business and direct channels is reflected in its reported revenue categories, which include business-to-business domestic sales, business-to-business international sales, direct-to-consumer domestic sales, and direct-to-consumer domestic rentals.

Through these channels, Inogen aims to make its respiratory therapy products accessible to patients who need oxygen therapy or sleep-related respiratory support in the homecare setting. The company’s financial disclosures show that business-to-business customers, both domestic and international, represent a significant driver of its sales revenue.

Homecare respiratory and sleep-therapy positioning

Inogen’s public statements emphasize its role in home respiratory care. The launch of the Voxi 5 stationary oxygen concentrator is described as expanding its product portfolio and market potential by complementing its line of portable oxygen concentrators and leveraging existing sales channels. Voxi 5 is characterized as a stationary oxygen concentrator designed to deliver continuous flow oxygen in a compact form factor for long-term care patients in the United States.

The introduction of Aurora CPAP masks marks Inogen’s entry into the sleep-therapy market, specifically targeting obstructive sleep apnea. The Aurora mask portfolio includes full-face, nasal cushion, and nasal pillows configurations, which are intended to address diverse patient needs when using CPAP devices. Inogen states that Aurora masks are engineered for comfort, reliability, and usability, and that they are compatible with most CPAP devices. This expansion supports the company’s stated strategy to grow its respiratory care portfolio and broaden its presence in home respiratory and sleep therapy.

Technology, development, and operations

Inogen’s financial statements and commentary show ongoing investment in research and development, as well as sales and marketing and general and administrative functions. The company reports research and development expenses as a component of operating expenses, reflecting its efforts to advance its product pipeline and respiratory therapy offerings. It has also highlighted initiatives such as the Inogen Patient Portal, which is designed to give patients self-service tools to manage insurance details, order accessories, and access support resources.

In addition, Inogen has reported initiatives related to airway clearance devices, such as a limited market release of the Simeox airway clearance device in the United States, further illustrating its focus on technologies that support respiratory care in home and related settings. The company’s disclosures also reference digital health and connected device capabilities at the leadership level, signaling attention to integrating devices, data, and user experience in its product roadmap.

Financial reporting and public company status

Inogen is listed on the Nasdaq under the ticker symbol INGN and files periodic reports and current reports with the U.S. Securities and Exchange Commission (SEC). The company provides quarterly and annual financial statements, including revenue by category (sales and rental), gross margin, operating expenses, net income or loss, cash flows, and balance sheet details. It also reports non-GAAP measures such as EBITDA and adjusted EBITDA, along with reconciliations to U.S. GAAP metrics.

Recent SEC Form 8-K filings have been used to furnish press releases related to quarterly financial results, including results for quarters ended March 31, June 30, and September 30, 2025. These filings confirm that Inogen continues to operate as a public company and to communicate material financial information to investors through both press releases and SEC submissions.

Geographic reach

Inogen describes itself as a global medical technology company and reports revenue from both domestic and international business-to-business customers. Its disclosures indicate that it generates a significant portion of its revenue in the United States, while also serving international markets through distributors and other partners. The company’s financial tables include revenue breakdowns by region and category, showing contributions from domestic and international business-to-business sales.

Role in the medical device and respiratory care industry

Within the broader manufacturing sector, Inogen fits into the surgical and medical instrument manufacturing industry, with a specific focus on respiratory therapy devices and accessories for homecare. Its product portfolio, including portable and stationary oxygen concentrators and CPAP masks, is aimed at supporting patients with chronic respiratory conditions and obstructive sleep apnea outside of acute-care settings.

By focusing on homecare respiratory products, Inogen’s role centers on enabling patients to receive respiratory therapy in their homes or long-term care environments. Its partnerships with home medical equipment providers, distributors, and prescribers, combined with direct rental and sales models, support the distribution and ongoing use of its devices.

Stock Performance

$5.30
-2.21%
-0.12
Last updated: at
-19.6%
Performance 1 year
$137.8M
26.0M
Shares outstanding As of October 29, 2026.

Inogen (INGN) closed at $5.30 on November 20, 2026. Over the past 12 months, the price has lost 19.6%.

See what a $1,000 investment in INGN would be worth today

Average down calculator for INGN

INGN Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Inogen has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, management, earnings date. View all INGN news →

Financial Highlights

Inogen generated $348.7M in revenue in FY2025, retaining a 44.2% gross margin, operating income reached -$30.2M (-8.7% operating margin), and net income was -$22.7M, reflecting a -6.5% net profit margin. Diluted earnings per share stood at -$0.86. The company generated -$11.2M in operating cash flow. The current ratio was 3.54, measuring current assets divided by current liabilities.

$348.7M
Revenue (FY2025)
-$22.7M
Net Income (FY2025)
-$11.2M
Operating Cash Flow

Upcoming Events

DEC
31
December 31, 2026 Financial

Fiscal Year End

End of Inogen Inc's Q4 and fiscal 2026 period; investors note this is the period end tied to the company revenue guidance.
YEAR
2027
2027 Operations

Cost Savings Target

Inogen Inc expects approximately $20M of annualized cost savings to be achieved by the end of 2027 under its cost program.

Inogen has 2 upcoming scheduled events. The next event, "Fiscal Year End", is scheduled for December 31, 2026 (in 40 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the INGN stock price.

Short Interest History

Last 12 Months

Short interest in Inogen (INGN) currently stands at 1.4 million shares, down 8.3% from the previous reporting period, representing 6.2% of the float. Since November 2025, short interest has increased by 86.5%.

Days to Cover History

Last 12 Months

Days to cover for Inogen (INGN) currently stands at 5.8 days, up 40.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 52.8%. Across the settlements charted above, it has ranged from 2.1 to 6.5 days.

INGN Company Profile & Sector Positioning

Inogen (INGN) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing INGN often look at related companies in the same sector, including MaxCyte, Inc. (MXCT), TriSalus Life Sciences, Inc. (TLSI), Neuronetics, Inc. (STIM), RxSight, Inc. (RXST), and Pulmonx Corporation (LUNG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INGN's relative position within its industry.

Frequently Asked Questions

The current stock price of Inogen (INGN) is $5.30 as of November 20, 2026.

The market cap of Inogen (INGN) is approximately $137.8M. Learn more about what market capitalization means .

The FY2025 revenue of Inogen (INGN) is $348.7M, from its most recent completed fiscal year.

The FY2025 net income of Inogen (INGN) is -$22.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Inogen (INGN) is -$0.86 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Inogen (INGN) is -$11.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Inogen (INGN) is -6.5% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Inogen (INGN) is -8.7% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Inogen (INGN) is 44.2% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Inogen (INGN), current assets divided by current liabilities, was 3.54 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Inogen (INGN) is $154.3M for FY2025, its most recent completed fiscal year.

The operating income of Inogen (INGN) is -$30.2M for FY2025, its most recent completed fiscal year. Learn about operating income.

Inogen Inc is a medical technology company that develops, manufactures, and markets respiratory therapy devices for use in the homecare setting. Its products support patients with chronic respiratory conditions by delivering oxygen therapy and related respiratory care, and are distributed through patients, prescribers, home medical equipment providers, and distributors.

Inogen Inc operates in the surgical and medical instrument manufacturing industry within the broader manufacturing sector. It focuses specifically on respiratory care devices and accessories intended for home and long-term care use.

Inogen states that it offers respiratory products for homecare use, including oxygen therapy devices and other respiratory therapy equipment. Recent company communications highlight a portfolio that includes portable oxygen concentrators, the Voxi 5 stationary oxygen concentrator for long-term care patients in the United States, and Aurora CPAP masks for patients indicated for obstructive sleep apnea.

Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available. It reports revenue from business-to-business domestic and international sales, direct-to-consumer domestic sales, and direct-to-consumer domestic rentals, reflecting both indirect and direct distribution models.

The Voxi 5 stationary oxygen concentrator is described by Inogen as a product designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. It complements the company’s line of portable oxygen concentrators, expands its product portfolio, and leverages existing sales channels to address additional use cases in home and long-term care environments.

Aurora CPAP masks are a product line introduced by Inogen as part of its expansion into the sleep-therapy market. The masks are intended for patients indicated for obstructive sleep apnea who use CPAP devices. The Aurora portfolio includes full-face, nasal cushion, and nasal pillows configurations, and is described as engineered for comfort, reliability, and usability with compatibility for most CPAP devices.

Inogen describes itself as a global medical technology company offering respiratory products for use in the homecare setting. It states that it supports patient respiratory care by developing, manufacturing, and marketing respiratory therapy devices, and by partnering with patients, prescribers, home medical equipment providers, and distributors to make these products widely available so patients can manage the impact of their disease.

Yes. Inogen Inc is a public company, and its common stock is listed on the Nasdaq under the ticker symbol INGN. The company files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10-Q, 10-K, and 8-K.

In its financial press releases and SEC filings, Inogen presents results under U.S. GAAP and also provides non-GAAP measures such as EBITDA, adjusted EBITDA, adjusted operating expense, adjusted loss from operations, adjusted net loss, and adjusted diluted EPS. The company includes reconciliations between GAAP and non-GAAP measures and explains that management uses these metrics to evaluate performance and compare results to forecasts and strategic plans.

Inogen’s financial statements separate revenue into sales revenue and rental revenue. Supplemental information further breaks revenue down by category, including business-to-business domestic sales, business-to-business international sales, direct-to-consumer domestic sales, and direct-to-consumer domestic rentals, reflecting both product sales and rental activity.